Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia

Approximately 20% of patients with acute myeloid leukaemia (AML) have a mutation in FMS-like-tyrosine-kinase-3 (FLT3). FLT3 is a trans-membrane receptor with a tyrosine kinase domain which, when activated, initiates a cascade of phosphorylated proteins including the SRC family of kinases. Recently o...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Sci Rep
Hlavní autoři: Pillinger, Genevra, Abdul-Aziz, Amina, Zaitseva, Lyubov, Lawes, Matthew, MacEwan, David J., Bowles, Kristian M., Rushworth, Stuart A.
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4544001/
https://ncbi.nlm.nih.gov/pubmed/26292723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep12949
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky